基石药业（02616.HK）百亿估值修复 中长线可期
Retrieved on:
Thursday, February 9, 2023
HongKong:2616
基石藥業（02616.HK）百億估值修復 中長線可期
Retrieved on:
Thursday, February 9, 2023
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
Retrieved on:
Monday, August 8, 2022
People, Antibody, III, Lung cancer, CSCO, Principal, Survival, Hospital, Risk, RECIST, Carboplatin, OS, Diagnosis, Immunoglobulin G, Cancer, Toxicity, The Lancet, Research, Pemetrexed, NSCLC, Patient, Chemoradiotherapy, Large-cell lung carcinoma, Principal investigator, WCLC, HKEX, Society, Paclitaxel, EGFR, Safety, LBA, ALK, PFS, Conference, Progression-free survival, Disease, Pharmaceutical industry, Engineered wood, Health insurance, Medical imaging, Greater China
Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.
Key Points:
- Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.
- Subgroup analyses demonstrated that sugemalimab was associated with clinical benefits regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.
- Sugemalimab couldbe safely and effectively used after concurrent or sequential chemoradiotherapy and become a standard of care in this setting for unresectable stage III NSCLC.
- Subgroup analyses demonstrated that sugemalimab was associated with clinical benefit regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
Retrieved on:
Monday, August 8, 2022
People, Antibody, III, Lung cancer, CSCO, Principal, Survival, Hospital, Risk, RECIST, Carboplatin, OS, Diagnosis, Immunoglobulin G, Cancer, Toxicity, The Lancet, Research, Pemetrexed, NSCLC, Patient, Chemoradiotherapy, Large-cell lung carcinoma, Principal investigator, WCLC, HKEX, Society, Paclitaxel, EGFR, Safety, LBA, ALK, PFS, Conference, Progression-free survival, Disease, Pharmaceutical industry, Engineered wood, Health insurance, Medical imaging, Greater China
Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.
Key Points:
- Subgroup analysis demonstrated clinical benefits in patients who had received either concurrent or sequential chemoradiotherapy prior to sugemalimab.
- Subgroup analyses demonstrated that sugemalimab was associated with clinical benefits regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.
- Sugemalimab couldbe safely and effectively used after concurrent or sequential chemoradiotherapy and become a standard of care in this setting for unresectable stage III NSCLC.
- Subgroup analyses demonstrated that sugemalimab was associated with clinical benefit regardless of whether patients received concurrent or sequential chemoradiotherapy prior to sugemalimab.